Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678426 | 1.00 | AKR1C4 (0.54) | AKR1C4AKR1C3AKR1C2TSHRSLC6A12 | |
| SCHEMBL5598360 | 0.79 | AKR1C4 (0.57) | AKR1C4AKR1C3AKR1C2TSHRSLC6A12 | |
| SCHEMBL3676689 | 0.76 | AKR1C4 (0.32) | AKR1C4AKR1C3AKR1C2HTT | |
| SCHEMBL2476814 | 0.75 | ACE (0.38) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2478853 | 0.75 | ACE (0.38) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL11863746 | 0.74 | AKR1C4 (0.68) | AKR1C4AKR1C3AKR1C2SLC6A12SLC6A11 | |
| SCHEMBL5597975 | 0.73 | AKR1C4 (0.57) | AKR1C4AKR1C3AKR1C2SLC6A12SLC6A11 | |
| SCHEMBL5080170 | 0.73 | CHRM2 (0.35) | — | |
| SCHEMBL11755975 | 0.73 | AKR1C4 (0.57) | AKR1C4AKR1C3AKR1C2SLC6A12SLC6A11 | |
| SCHEMBL2476808 | 0.72 | AKR1C4 (0.69) | AKR1C4AKR1C3AKR1C2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649107-B2 | Process for the preparation of cyclopentanone derivatives | FIRMENICH SA (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080214859-A1 | Process for the Preparation of Cyclopentanone Derivatives | FIRMENICH SA (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214859-A1 | Process for the Preparation of Cyclopentanone Derivatives | DHPS, CBR3, CBR1 | AKR1C4 6/4885AKR1C3 11/4885AKR1C2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.